{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:57:00Z","timestamp":1778569020647,"version":"3.51.4"},"reference-count":76,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HemaSphere"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec><jats:title>Abstract<\/jats:title><jats:p>Deregulated Janus Kinase 2 (JAK2) activation is central to the pathogenesis of most myeloproliferative neoplasms (MPNs), of which essential thrombocythemia (ET) is the most common entity. Patients with ET are risk\u2010stratified according to their risk of thrombo\u2010hemorrhagic complications. High\u2010risk patients are offered treatments to reduce their platelet count using cytoreductive therapy. The disease course is often long and therapy intolerance is not infrequent. Ruxolitinib, a Janus Kinase (JAK) 1\/JAK2\u00a0inhibitor, has demonstrated efficacy in patients with both myelofibrosis (MF) and polycythemia vera and is well tolerated. Side effects include predictable cytopenias and an augmented risk of infections. Ruxolitinib has been investigated in a small group of ET patients who were refractory\/intolerant to hydroxycarbamide (HC) and demonstrated improvements in both symptoms and splenomegaly. Of note, a proportion of treated patients (13.2%) also had a significant reduction in platelet counts. However, these results require further validation in comparison with conventional therapy. Recently, a randomized\u2010controlled phase 2 study (MAJIC\u2010ET) assessed the role of Ruxolitinib in patients refractory or intolerant to HC. This study revealed that Ruxolitinib demonstrated some clinical efficacy but was only superior in terms of symptom control. In clinical practice, some individuals with ET do exhaust all potential treatment options and there may well be a role for Ruxolitinib in such patients or those with a significant symptom burden. However, in the wider context the goal of therapy with the use of JAK inhibitor therapy in ET needs to be defined carefully and we explore this within this timely review article.<\/jats:p><\/jats:sec>","DOI":"10.1097\/hs9.0000000000000056","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T18:12:20Z","timestamp":1528827140000},"source":"Crossref","is-referenced-by-count":17,"title":["Ruxolitinib for the Treatment of Essential Thrombocythemia"],"prefix":"10.1002","volume":"2","author":[{"given":"Arief","family":"Gunawan","sequence":"first","affiliation":[{"name":"Guy's and St Thomas\u2019 NHS Foundation Trust London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Harrington","sequence":"additional","affiliation":[{"name":"Guy's and St Thomas\u2019 NHS Foundation Trust London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Garcia\u2010Curto","sequence":"additional","affiliation":[{"name":"Guy's and St Thomas\u2019 NHS Foundation Trust London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donal","family":"McLornan","sequence":"additional","affiliation":[{"name":"Guy's and St Thomas\u2019 NHS Foundation Trust London UK"},{"name":"King's College Hospital NHS Foundation Trust London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepti","family":"Radia","sequence":"additional","affiliation":[{"name":"Guy's and St Thomas\u2019 NHS Foundation Trust London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Harrison","sequence":"additional","affiliation":[{"name":"Guy's and St Thomas\u2019 NHS Foundation Trust London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,8]]},"reference":[{"key":"e_1_2_8_2_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13605"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312542"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311347"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.35"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-661983"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-661835"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23895"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-403279"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V64.5.981.981"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12967"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.983098"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22365"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.3863"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.8436"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761999"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21594"},{"key":"e_1_2_8_22_1","doi-asserted-by":"crossref","unstructured":"MudireddyM ShahS LashoTet al. Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical cytogenetic molecular and prognostic comparisons.Br J Haematol2017; Epub ahead of print.","DOI":"10.1111\/bjh.14838"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-444067"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485888"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.89"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-263319"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.146654"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504273321704"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1602"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043800"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-443770"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.174672"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.280"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04542.x"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.9.3370"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404743"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02188.x"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-484832"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.71"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1088831"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1590"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.63"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503479"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310523"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08266.x"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12416"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3082-y"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214957"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3264"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010389469"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011405663"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.033787"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002028"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.115840"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-624536"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409002"},{"key":"e_1_2_8_59_1","unstructured":"KiladjianJJ VanucchiAM GriesshammerMet al.Ruxolitinib versus best available therapy in patients with polycythaemia vera: 80\u2010week follow\u2010up from the RESPONSE trial. Paper presented at: 20th Congress of the European Hematology Association Vienna Austria; June 22 2015."},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-015-0284-z"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14382"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30558-7"},{"key":"e_1_2_8_63_1","doi-asserted-by":"crossref","unstructured":"PassamontiF RumiE Della PortaMGet al.INCB018424 a selective inhibitor of JAK1 and JAK2 downregulates the expression of Leukocyte Alkaline Phosphatase (LAP) on circulating granulocytes in patients with polycythemia vera and essential thrombocythemia (Abstract). Paper presented at: 51st ASH Annual Meeting and Exposition 2009 New Orleans LA.","DOI":"10.1182\/blood.V114.22.2905.2905"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-785790"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-1604"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2014-204950"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1302895"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.235"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.916273"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12878-015-0029-1"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1302135"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13373"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3198"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-484642"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.120"},{"key":"e_1_2_8_76_1","doi-asserted-by":"crossref","unstructured":"LeibundgutEO HaubitzM BurringtonBet al.Dynamics of mutations in patients with ET treated with Imetelstat. 57th ASH Annual meeting and Exposition Orlando FL;2015.","DOI":"10.1182\/blood.V126.23.57.57"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.128918"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1097\/HS9.0000000000000056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T02:31:15Z","timestamp":1709865075000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1097\/HS9.0000000000000056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1097\/HS9.0000000000000056"],"URL":"https:\/\/doi.org\/10.1097\/hs9.0000000000000056","archive":["Portico"],"relation":{},"ISSN":["2572-9241","2572-9241"],"issn-type":[{"value":"2572-9241","type":"print"},{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]},"article-number":"e56"}}